Article
Pharmacology & Pharmacy
Hsin-Yu Kuo, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, Chiao-Hsiung Chuang, I-Chin Wu, Juei-Seng Wu, Tzu-Chun Hong, Ming-Tsung Hsieh, Yang-Cheng Lee, Hung-Tsung Wu, Hong-Ming Tsai
Summary: This study investigated the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients. The results showed that pembrolizumab had a significantly higher objective response rate and overall survival compared to nivolumab.
Article
Oncology
Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R. Malan, Andrew Mant, Vinay Sharma, Hong Shue, Andrea Tazbirkova, Miguel-Angel Berciano-Guerrero, Chaiyut Charoentum, Stephane Dalle, Arunee Dechaphunkul, Oleksandr Dudnichenko, Piotr Koralewski, Iwona Lugowska, Henri Montaudie, Eva Munoz-Couselo, Virote Sriuranpong, James Oliviero, Jayesh Desai
Summary: Cosibelimab demonstrated clinically meaningful objective response rate and duration of response in patients with metastatic CSCC, with a manageable safety profile.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Wenwen Yang, Caining Lei, Shaoming Song, Wutang Jing, Chuanwei Jin, Shiyi Gong, Hongwei Tian, Tiankang Guo
Summary: There has been a paradigm shift in cancer treatment with the emergence of immune checkpoint inhibitors, targeting PD-1 and PD-L1 pathways. The efficacy of these drugs may be related to PD-L1 expression and other emerging biomarkers. Customized medication models and predictive markers are becoming the new trend in malignant tumor immunotherapy.
CANCER CELL INTERNATIONAL
(2021)
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Chu-Ling Li, Yong Song
Summary: Immunotherapy has greatly impacted the treatment of non-small cell lung cancer, with combination strategies showing promising clinical outcomes. However, there is still room for improvement in response rates, necessitating exploration of alternative combination models and candidate selection strategies.
CHINESE MEDICAL JOURNAL
(2021)
Review
Oncology
Dhananj ay Yadav, Minseok Kwak, Pallavi Singh Chauhan, Nidhi Puranik, Peter C. W. Lee, Jun-O Jin
Summary: Cancer is the second leading cause of death worldwide. Traditional approaches like surgery, chemotherapy, and radiotherapy have been commonly used for cancer treatment. Cancer immunotherapy, a novel therapeutic modality, boosts the immune responses of patients against malignancy. Recent advances in nanotechnology have facilitated the development of successful and efficient anticancer drug systems based on nanoparticles.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Shogo Takei, Akihito Kawazoe, Kohei Shitara
Summary: This review examines the current status of immunotherapy in advanced gastric cancer (AGC), focusing on molecular and immunological profiles, biomarkers, major clinical trials, and novel immunotherapies. Immune checkpoint inhibitors have demonstrated good clinical benefit in AGC, but resistance remains a challenge.
Review
Immunology
Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu
Summary: Urothelial carcinoma (UC) is a common malignant tumor. Platinum-based chemotherapy has been the standard treatment for metastatic UC, but immune checkpoint inhibitors (ICIs) offer hope for patients unfit for platinum therapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Oncology
Wei Xiong, Yunfeng Zhao, He Du, Xuejun Guo
Summary: Immunotherapy has made significant advancements in the treatment of lung cancer, with challenges including the selection of appropriate ICI agents, use of immune biomarkers, and determining the optimal combination and sequence of treatments.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Pedro Iglesias, Inmaculada Peiro, Betina Biagetti, Miguel Paja-Fano, Diana Ariadel Cobo, Carlos Garcia Gomez, Manuel Mateu-Salat, Idoia Genua, Margarita Majem, Mariona Riudavets, Javier Gavira, Cristina Lamas, Antia Fernandez Pombo, Fernando Guerrero-Perez, Carles Villabona, Jose Manuel Cabezas Agricola, Susan M. Webb, Juan J. Diez
Summary: Recent research has shown that immune checkpoint inhibitor (ICI) therapy may lead to central adrenal insufficiency (AI) due to isolated adrenocorticotropic hormone (ACTH) deficiency (IAD). This study aimed to analyze the prevalence, clinical characteristics, and therapeutic outcomes of cancer patients with IAD induced by ICI therapy. It was found that IAD develops around 7 months after starting the treatment, mainly anti-PD1 antibodies, and recovery of the corticotropic axis function should not be expected.
ENDOCRINE-RELATED CANCER
(2021)
Article
Oncology
Junsik Park, Jung Bok Lee, Myong Cheol Lim, Byoung-Gie Kim, Jae-Weon Kim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Sang Yoon Park, Jung-Yun Lee
Summary: The study demonstrated promising antitumor activity and safety of durvalumab plus tremelimumab combined with neoadjuvant chemotherapy in patients with advanced ovarian cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jacqueline E. Mann, Liliana Lucca, Matthew R. Austin, Ross D. Merkin, Marie E. Robert, Badr Al Bawardy, Khadir Raddassi, Lilach Aizenbud, Nikhil S. Joshi, David A. Hafler, Clara Abraham, Kevan C. Herold, Harriet M. Kluger
Summary: Immune checkpoint inhibitors (ICIs) are commonly used in cancer treatment, but they can cause immune-related adverse events, such as colitis. This study investigated the changes in immune environments during the progression and treatment of colitis induced by pembrolizumab. The findings suggest that specific T-cell subsets might contribute to inflammation and response to immune suppression, highlighting the importance of further exploring the colon immune environment and evaluating biologics for ICI-colitis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Matteo Sensi, Marcello Berto, Sara Gentile, Marcello Pinti, Andrea Conti, Giovanni Pellacani, Carlo Salvarani, Andrea Cossarizza, Carlo Augusto Bortolotti, Fabio Biscarini
Summary: The study presented a novel immunosensor for the quantitative and selective detection of ADAs against a drug, which may enhance the effectiveness of clinical treatment.
CHEMICAL COMMUNICATIONS
(2021)
Review
Pharmacology & Pharmacy
Joao Calmeiro, Mylene A. Carrascal, Adriana Ramos Tavares, Daniel Alexandre Ferreira, Celia Gomes, Maria Teresa Cruz, Amilcar Falcao, Bruno Miguel Neves
Summary: Immunotherapy has led to a paradigm shift in the treatment of malignancies, especially through the combination of multiple immunotherapeutic strategies for superior clinical outcomes.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Oncology
James Godfrey, Xiufen Chen, Nicole Sunseri, Alan Cooper, Jovian Yu, Arina Varlamova, Dmitry Zarubin, Yuriy Popov, Connor Jacobson, Ekaterina Postovalova, Zhongmin Xiang, Krystle Nomie, Aleksander Bagaev, Girish Venkataraman, Yuanyuan Zha, Sravya Tumuluru, Sonali M. Smith, Justin P. Kline
Summary: This study reveals that TIGIT is widely expressed in lymphoma-infiltrating T cells (LITs) and frequently coexpressed with PD-1. In DLBCL, TIGIT(+) LITs often have significant contact with malignant B cells and exhibit dysfunctional cytokine production upon restimulation. In mouse experiments, combined blockade of PD-1 and TIGIT leads to complete rejection of lymphomas and significantly prolongs survival compared to monoblockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)